Study of TRAVATAN in Subjects With Iris Pigmentation Changes

• Status: Terminated
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ophthalmic Solutions; Travoprost

Criteria

Inclusion:

• Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension;

• Has experienced an iris pigmentation change while dosing with TRAVATAN;

• Currently dosing with TRAVATAN;

• Other protocol-defined inclusion criteria may apply.

Exclusion:

• Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension;

• Not currently using TRAVATAN;

• Females of childbearing potential if pregnant, breast-feeding, or not using highly effective birth control measures;

• History of any severe ocular pathology (including severe dry eye);

• Other protocol-defined exclusion criteria may apply.